

# BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

APRIL 25-26, 2023



**BBHIC  
2023**





## **BLOOM BURTON & CO.**

**Exists to accelerate returns in the healthcare sector for both companies and investors. There is no greater illustration of the power of our platform than this conference, which has grown into Canada's flagship healthcare investment and networking event over the past decade.**

# W E L C O M E

Welcome to the 2023 Bloom Burton & Co. Healthcare Investor Conference!

For almost fifteen years, Bloom Burton & Co. has been solely dedicated to accelerating the path to monetization for healthcare companies and investors, as we deliver our many services such as raising equity and debt capital, M&A advisory, equity research, sales and trading, scientific and business advisory, principal investing and the creation/incubation of entirely new companies. We work with companies of every stage of development and in every area of healthcare, including biotechnology, pharmaceuticals, medical technology, healthcare services, digital health, research and manufacturing tools, pharma services, as well as animal and consumer health.

There is no greater expression of the breadth of our work than the Bloom Burton & Co. Healthcare Investor Conference, which has become Canada's flagship event for global investors to meet Canada's leading companies, and the ecosystem which supports them.

Last year, we also hosted the sixth edition of the Bloom Burton Award Gala, which has cemented itself as the preeminent award to celebrate each year's most important contributor in the Canadian healthcare sector. We hope to see you all at the black-tie 2023 Bloom Burton Award Gala on September 28, 2023 at the Four Seasons Hotel in Toronto. Our three finalists for this year's award will be announced this week, during the lunch hour!

We are humbled to serve as a catalyst for our industry and we are so proud of our brilliant and dedicated team, who work tirelessly to produce exceptional work and support positive outcomes for all of our clients. Our entire team is here for you this week as you make new connections and plan for the success of the healthcare sector in Canada and beyond.

---

**We wish you a wonderful conference!**

*Brian and Jolyon*

---

# TABLE OF CONTENTS

|   |    |
|---|----|
| About   | 3  |
| Agenda  | 4  |
| Keynote Speaker   | 6  |
| Investing in R&D-Stage<br>Healthcare Companies Panel        | 8  |
| Investing in Commercial-Stage<br>Healthcare Companies Panel | 11 |
| Presenting Companies  | 16 |
| About Bloom Burton & Co.                                    | 52 |
| Sponsors  | 56 |

## WiFi

---

Network Name  
Bloom Burton & Co.

Access Code  
BBHIC2023

# ABOUT



## 2023 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

The 2023 Bloom Burton & Co. Healthcare Investor Conference takes place on April 25-26, 2023 at the Metro Toronto Convention Centre.

Approximately 66 of Canada's premier publicly-traded and venture-backed private companies as well as the most promising pre-venture companies in the healthcare industry are invited to attend and present to our audience of Canadian, U.S. and international investors.

At the conference, investors and company management have the opportunity to meet one-on-one. We also provide a stage for industry leaders to discuss the latest news and share insights on the ups and downs of the market and the state of the global healthcare industry.

# AGENDA

## TUESDAY APRIL 25

Registration opens at 8:00 AM

|                 |                                       |                      |
|-----------------|---------------------------------------|----------------------|
| 8:30AM          | <b>Breakfast and Opening Remarks</b>  | PLENARY ROOM 106/107 |
| 8:30AM - 9:30AM | <b>Toronto Stock Exchange Opening</b> | PLENARY ROOM 106/107 |

### ROOM 104 C/D

|          |   |
|----------|---|
| 9:30 AM  | NASDAQ: ABCL<br><b>AbCellera Biologics</b><br>BIOTECHNOLOGY   |
| 10:00 AM | NASDAQ: KDNY<br><b>Chinook Therapeutics</b><br>BIOTECHNOLOGY  |
| 10:30 AM | TSX: EPRX<br><b>Eupraxia Pharmaceuticals</b><br>BIOTECHNOLOGY |
| 11:00 AM | NASDAQ: XENE<br><b>Xenon Pharmaceuticals</b><br>BIOTECHNOLOGY |
| 11:30 AM | TSX-V: MSCL<br><b>Satellos Bioscience</b><br>BIOTECHNOLOGY    |

### ROOM 104 B

|          |   |
|----------|---|
| 9:30 AM  | TSX: MDP<br><b>Medexus Pharmaceuticals</b><br>SPECIALTY PHARMACEUTICALS         |
| 10:00 AM | TSX: DHT.UN / DHT.U<br><b>DRI Healthcare Trust</b><br>SPECIALTY PHARMACEUTICALS |
| 10:30 AM | TSX: CPH<br><b>Cipher Pharmaceuticals</b><br>SPECIALTY PHARMACEUTICALS          |
| 11:00 AM | CSE: VPH<br><b>Valeo Pharma</b><br>SPECIALTY PHARMACEUTICALS                    |
| 11:30 AM | TSX: HLS<br><b>HLS Therapeutics</b><br>SPECIALTY PHARMACEUTICALS                |

### ROOM 104 A

|          |  |
|----------|--|
| 9:30 AM  | PRIVATE<br><b>Nicoya Lifesciences</b><br>TOOLS                                     |
| 10:00 AM | PRIVATE<br><b>Virica Biotech</b><br>TOOLS  |
| 10:30 AM | PRIVATE<br><b>ARTMS</b><br>TOOLS   |
| 11:00 AM | PRIVATE<br><b>AtomVie Global Radiopharma</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH |
| 11:30 AM | TSX: TH / NASDAQ: THTX<br><b>Theratechnologies</b><br>BIOTECHNOLOGY                |

|         |              |                      |
|---------|--------------|----------------------|
| 12:00PM | <b>Lunch</b> | PLENARY ROOM 106/107 |
|---------|--------------|----------------------|

|                  |   |                      |
|------------------|---|----------------------|
| 12:30PM - 1:30PM | <b>Panel: Investing in R&amp;D-Stage Healthcare Companies</b> | PLENARY ROOM 106/107 |
|------------------|---|----------------------|

|                                     |   |  |   |
|-------------------------------------|---|--|---|
| <b>Michelle Doig</b><br>OMEGA FUNDS | <b>Emily Janvey</b><br>ABINGWORTH / CARLYLE | <b>Stefan Vitorovic</b><br>VIDA VENTURES | <b>Edward Zhong</b><br>LOGOS CAPITAL MANAGEMENT |
|-------------------------------------|---|--|---|

### ROOM 104 C/D

|         |  |
|---------|--|
| 1:30 PM | PRIVATE<br><b>Acuitas Therapeutics</b><br>BIOTECHNOLOGY                    |
| 2:00 PM | NASDAQ: EPIX<br><b>ESSA Pharma</b><br>BIOTECHNOLOGY                        |
| 2:30 PM | NYSE: ZYME<br><b>Zymeworks</b><br>BIOTECHNOLOGY                            |
| 3:00 PM | NASDAQ: FUSN<br><b>Fusion Pharmaceuticals</b><br>BIOTECHNOLOGY             |
| 3:30 PM | TSX: MDNA / NASDAQ: MDNA<br><b>Medicenna Therapeutics</b><br>BIOTECHNOLOGY |
| 4:00 PM | TSX: CRRX<br><b>CareRx</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH           |

### ROOM 104 B

|         |  |
|---------|--|
| 1:30 PM | TSX: GUD<br><b>Knight Therapeutics</b><br>SPECIALTY PHARMACEUTICALS        |
| 2:00 PM | TSX-V: RX<br><b>BioSyent</b><br>SPECIALTY PHARMACEUTICALS                  |
| 2:30 PM | TSX-V: WOLF<br><b>Grey Wolf Animal Health</b><br>SPECIALTY PHARMACEUTICALS |
| 3:00 PM | PRIVATE<br><b>Searchlight Pharma</b><br>SPECIALTY PHARMACEUTICALS          |
| 3:30 PM | PRIVATE<br><b>FORUS Therapeutics</b><br>SPECIALTY PHARMACEUTICALS          |
| 4:00 PM | PRIVATE<br><b>KYE Pharmaceuticals</b><br>SPECIALTY PHARMACEUTICALS         |

### ROOM 104 A

|         |  |
|---------|--|
| 1:30 PM | PRIVATE<br><b>Gandeeva Therapeutics</b><br>BIOTECHNOLOGY   |
| 2:00 PM | PRIVATE<br><b>Thryv Therapeutics</b><br>BIOTECHNOLOGY      |
| 2:30 PM | PRIVATE<br><b>Entos Pharmaceuticals</b><br>BIOTECHNOLOGY   |
| 3:00 PM | PRIVATE<br><b>Zucara Therapeutics</b><br>BIOTECHNOLOGY     |
| 3:30 PM | PRIVATE<br><b>KisoJi Biotechnology</b><br>BIOTECHNOLOGY    |
| 4:00 PM | PRIVATE<br><b>Radiant Biotherapeutics</b><br>BIOTECHNOLOGY |

|        |                           |                                |
|--------|---------------------------|--------------------------------|
| 5:00PM | <b>Cocktail Reception</b> | ARIA RISTORANTE<br>25 YORK ST. |
|--------|---------------------------|--------------------------------|

# AGENDA

## WEDNESDAY APRIL 26

Registration opens at 8:00 AM

|                        |  |                      |
|------------------------|--|----------------------|
| <b>8:30AM</b>          | <b>Breakfast and Opening Remarks</b>                                 | PLENARY ROOM 106/107 |
| <b>8:30AM – 9:30AM</b> | <b>Keynote Speaker</b><br>John Maraganore<br>ALNYLAM PHARMACEUTICALS | PLENARY ROOM 106/107 |

### ROOM 104 C/D

|                 |   |
|-----------------|---|
| <b>9:30 AM</b>  | <b>TSX: WELL</b><br><b>WELL Health Technologies</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH |
| <b>10:00 AM</b> | <b>PRIVATE</b><br><b>AlayaCare</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH                  |
| <b>10:30 AM</b> | <b>PRIVATE</b><br><b>Bayshore HealthCare</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH        |
| <b>11:00 AM</b> | <b>TSX-V: THINK</b><br><b>Think Research</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH        |
| <b>11:30 AM</b> | <b>PRIVATE</b><br><b>Canary Medical</b><br>MEDICAL TECHNOLOGY                             |

### ROOM 104 B

|                 |   |
|-----------------|---|
| <b>9:30 AM</b>  | <b>TSX-V: HTL</b><br><b>Hamilton Thorne</b><br>MEDICAL TECHNOLOGY               |
| <b>10:00 AM</b> | <b>TSX: PRN / NASDAQ: PROF</b><br><b>Profound Medical</b><br>MEDICAL TECHNOLOGY |
| <b>10:30 AM</b> | <b>TSX: OPS</b><br><b>OpSens</b><br>MEDICAL TECHNOLOGY                          |
| <b>11:00 AM</b> | <b>TSX-V: PINK</b><br><b>Perimeter Medical Imaging</b><br>MEDICAL TECHNOLOGY    |
| <b>11:30 AM</b> | <b>TSX: MBX</b><br><b>Microbix Biosystems</b><br>MEDICAL TECHNOLOGY             |

### ROOM 104 A

|                 |   |
|-----------------|---|
| <b>9:30 AM</b>  | <b>PRIVATE</b><br><b>Triumvira Immunologics</b><br>BIOTECHNOLOGY  |
| <b>10:00 AM</b> | <b>PRIVATE</b><br><b>Ventus Therapeutics</b><br>BIOTECHNOLOGY     |
| <b>10:30 AM</b> | <b>PRIVATE</b><br><b>Deep Genomics</b><br>BIOTECHNOLOGY           |
| <b>11:00 AM</b> | <b>PRIVATE</b><br><b>Inversago Pharma</b><br>BIOTECHNOLOGY        |
| <b>11:30 AM</b> | <b>PRIVATE</b><br><b>Congruence Therapeutics</b><br>BIOTECHNOLOGY |

|                |              |                      |
|----------------|--------------|----------------------|
| <b>12:00PM</b> | <b>Lunch</b> | PLENARY ROOM 106/107 |
|----------------|--------------|----------------------|

|                                     |  |  |  |
|-------------------------------------|--|--|--|
| <b>12:30PM – 1:30PM</b>             | <b>Panel: Investing in Commercial-Stage Healthcare Companies</b> | PLENARY ROOM 106/107                             |  |
| <b>Kyle Dempsey</b><br>MVM PARTNERS | <b>Karimah Es Sabar</b><br>QUARK VENTURE                         | <b>Aly Hadibhai</b><br>ONCAP MANAGEMENT PARTNERS | <b>Michael Reslinski</b><br>SIXTH STREET |

### ROOM 104 C/D

|                |   |
|----------------|---|
| <b>1:30 PM</b> | <b>TSX: VHI</b><br><b>VitalHub</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH                          |
| <b>2:00 PM</b> | <b>TSX: LSPK</b><br><b>LifeSpeak</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH                        |
| <b>2:30 PM</b> | <b>TSX: VMD / NASDAQ: VMD</b><br><b>VieMed Healthcare</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH   |
| <b>3:00 PM</b> | <b>TSX-V: NEWU</b><br><b>Newtopia</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH                       |
| <b>3:30 PM</b> | <b>TSX-V: DOC</b><br><b>CloudMD Software &amp; Services</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH |
| <b>4:00 PM</b> | <b>TSX-V: NPTH</b><br><b>NeuPath Health</b><br>HEALTHCARE SERVICES/DIGITAL HEALTH                 |

### ROOM 104 B

|                |   |
|----------------|---|
| <b>1:30 PM</b> | <b>TSX: ATE</b><br><b>Antibe Therapeutics</b><br>BIOTECHNOLOGY                  |
| <b>2:00 PM</b> | <b>NASDAQ: PNT</b><br><b>POINT Biopharma</b><br>BIOTECHNOLOGY                   |
| <b>2:30 PM</b> | <b>TSX: REUN / NASDAQ: REUN</b><br><b>Reunion Neuroscience</b><br>BIOTECHNOLOGY |
| <b>3:00 PM</b> | <b>CSE: BETR</b><br><b>BetterLife Pharma</b><br>BIOTECHNOLOGY                   |
| <b>3:30 PM</b> | <b>TSX: APLI</b><br><b>Appili Therapeutics</b><br>BIOTECHNOLOGY                 |
| <b>4:00 PM</b> | <b>TSX: IGX</b><br><b>IntelGenX</b><br>SPECIALTY PHARMACEUTICALS                |

### ROOM 104 A

|                |  |
|----------------|--|
| <b>1:30 PM</b> | <b>PRIVATE</b><br><b>Synaptive Medical</b><br>MEDICAL TECHNOLOGY             |
| <b>2:00 PM</b> | <b>PRIVATE</b><br><b>Clarius</b><br>MEDICAL TECHNOLOGY                       |
| <b>2:30 PM</b> | <b>PRIVATE</b><br><b>Exact Imaging</b><br>MEDICAL TECHNOLOGY                 |
| <b>3:00 PM</b> | <b>PRIVATE</b><br><b>IntelliJoint Surgical</b><br>MEDICAL TECHNOLOGY         |
| <b>3:30 PM</b> | <b>PRIVATE</b><br><b>Panthera Dental</b><br>MEDICAL TECHNOLOGY               |
| <b>4:00 PM</b> | <b>PRIVATE</b><br><b>Adaptiiv Medical Technologies</b><br>MEDICAL TECHNOLOGY |

---

# KEYNOTE SPEAKER

WEDNESDAY, APRIL 26, 2023

8:30 AM - 9:30 AM

PLENARY ROOM 106/107



**JOHN  
MARAGANORE**

Founder

Alnylam Pharmaceuticals

---

## ABOUT

John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. The fifth RNAi therapeutic, AMVUTTRA®, was approved in mid-2022. At Alnylam, he also led the company's value creation strategy, building over \$25B in market capitalization and forming over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board.

Prior to Alnylam, John was at Millennium Pharmaceuticals, Inc., where he was responsible for the company's product franchises in oncology, and cardiovascular, inflammatory and metabolic diseases, in addition to leadership of M&A, strategy, and biotherapeutics functions. Before Millennium, he held scientific and business roles at Biogen, Inc. where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company.

John is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, a Senior Advisor for Blackstone Life Sciences, and an Advisor for M28. He is also member of the Board of Directors of publicly traded companies, including Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, ProKidney Corp., and Takeda Pharmaceuticals. He is also on the Board of a number of private companies – including Aerium Therapeutics, Aera Therapeutics (Chair), Aitia (Chair), Hemab Therapeutics (Chair), Orbital Therapeutics (Executive Chair), and Versanis Bio. As the principal of JMM Innovation, LLC, John serves as a strategic advisor to a number of innovative biotechnology companies, including mentorship of CEOs in their mission to advance science and innovation for patients.

John is on the Board of the Biotechnology Innovation Organization, or "BIO," where he was Chair from 2017-2019 and is Chair Emeritus. In addition, he serves on the Board of the Termeer Foundation – committed to continuing the legacy of the late Henri A. Termeer, as Chair of the n-Lorem Foundation Advisory Council – committed to meeting the needs of patients with nano-rare diseases, on the Advisory Board of Ariadne Labs – advancing global health system innovations, and as an advisor to Nucleate – a student-led organization facilitating the formation of pioneering life sciences companies

John received his BA, MS and PhD in biochemistry and molecular biology at the University of Chicago.

---

# INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL

TUESDAY, APRIL 25, 2023

12:30 PM - 1:30 PM

PLENARY ROOM 106/107

**MICHELLE DOIG**  
OMEGA FUNDS

**EMILY JANVEY**  
ABINGWORTH/CARLYLE

**STEFAN VITOROVIC**  
VIDA VENTURES

**EDWARD ZHONG**  
LOGOS CAPITAL MANAGEMENT

# PANELISTS

## Investing in R&D-Stage Healthcare Companies



### MICHELLE DOIG

Partner,  
Head of Corporate Development  
**Omega Funds**

Michelle Doig is a Partner and Head of Corporate Development at Omega Funds, a leading US-based life sciences venture capital firm with ~\$2 billion in AUM. Michelle has been heavily involved with Portfolio companies Replimune, Morphic, Nuvation and Artios.

Before joining Omega Funds in 2016, Michelle was Director of Corporate Finance at Third Rock Ventures where she helped numerous portfolio companies, including Global Blood Therapeutics, MyoKardia, Afferent, Editas, Jounce and Blueprint with their financing/strategies. Prior to Third Rock, Michelle was a Principal at Abingworth in London and Boston.

Michelle began her career as a Life Sciences Investment Banker with Morgan Stanely (Toronto/NYC), JP Morgan H&Q (NYC/San Francisco) and then Lehman Brothers (London).



### EMILY JANVEY

Managing Director

### Abingworth/Carlyle

Emily Janvey leads Clinical Co-Development deals with pharma and biotechs to advance late-stage clinical trials. Emily joined Abingworth from Iconiq Capital where she served as Health Care Portfolio Manager across asset classes.

Prior to Iconiq, Emily was a Director at KKR where she led the Health Care Royalty and Income platform and was a member of the America's Health Care Private Equity team serving on multiple corporate boards. Prior to joining KKR, Emily was a Vice President at Sixth Street Partners where she focused on royalty and credit financing to public and private life sciences companies. Emily started her career as a consultant in the health care practices at McKinsey and Company.

Emily earned her MD and MBA from the University of Pennsylvania and her BA in neuroscience from Hamilton College.

# PANELISTS

Investing in R&D-Stage Healthcare Companies



## STEFAN VITOROVIC

Co-Founder,  
Managing Director  
**Vida Ventures**

Stefan Vitorovic is Co-Founder and Managing Director at Vida Ventures, a life sciences company formation and investing firm.

Prior to co-founding Vida Ventures, Stefan was an investment professional at Third Rock Ventures, an early-stage life sciences venture capital firm. At Third Rock, he was responsible for new company formation and strategic finance. There he was part of the founding team of Decibel Therapeutics.

Before Third Rock, Stefan was an investor at TPG Capital, where he focused on majority, control stakes in scale healthcare companies. At TPG, Stefan worked on a variety of equity and debt financings. Prior to TPG, he was an investment banker at Credit Suisse's healthcare investment banking group.

Stefan received his BS with Honours in Biological Sciences at Stanford University. He completed his MS in Biology at Stanford, where he conducted biomedical research at Stanford Medical School. Stefan later received his MBA from Harvard Business School.



## EDWARD ZHONG

Managing Member,  
Head of Data Science  
**Logos Capital Management**

Edward Zhong serves as Managing Member and heads Logos Capital Management's Data Science effort. Prior to co-founding Logos, Edward was the founding data scientist at Farallon Capital Management, where he helped lead the development of clinical trial models, analysis of large datasets, and antitrust models for M&A situations.

Edward holds a BA in Economics from Harvard University and a PhD in Economics from the University of Madison-Wisconsin.

---

# INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL

WEDNESDAY, APRIL 26, 2023

12:30 PM - 1:30 PM

PLENARY ROOM 106/107



**KYLE DEMPSEY**  
MVM PARTNERS



**KARIMAH ES SABAR**  
QUARK VENTURE



**ALY HADIBHAI**  
ONCAP MANAGEMENT PARTNERS



**MICHAEL RESLINSKI**  
SIXTH STREET

# PANELISTS

## Investing in Commercial-Stage Healthcare Companies



**KYLE DEMPSEY**

Partner

### MVM Partners

Kyle Dempsey joined MVM Partners in 2017, a commercial stage investment fund that invests broadly across the life sciences and healthcare sectors, including medical devices, pharmaceuticals, diagnostics, digital health, health IT, life science tools, contract research, contract manufacturing, among other areas.

Prior to joining MVM, Kyle was a consultant at Bain & Company, working mainly in the healthcare practice to support medical device and healthcare provider clients. Kyle completed MD studies at Harvard Medical School and MBA studies at Harvard Business School. He also holds an AB in biochemistry from Bowdoin College.



**KARIMAH ES SABAR**

Chief Executive Officer,  
General Partner  
**Quark Venture**

Karimah Es Sabar is the founding CEO & General Partner at Quark Venture LP, a global venture capital firm, and Director of the Global Health Sciences Fund focused on bioscience investment in therapeutics, vaccines, medical devices, digital health, AI and convergent disruptive technology companies.

Prior to joining Quark Venture, Karimah was CEO & President of the Centre for Drug Research and Development; CEO & President of LifeSciences BC; and she has held several senior management positions in the biopharmaceutical industry, most notably at Sanofi Pasteur where she led marketing and business development, and was later head of the international division. She also co-founded and enabled several startup companies.

Karimah has received multiple awards and recognitions for her leadership and pioneering work. She holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management; a MSc degree in Neurochemistry from the Institute of Psychiatry, University of London, England; and a BSc Joint Honours degree in Biochemistry/Chemistry from the University of Salford in Manchester, England.

# PANELISTS

Investing in Commercial-Stage Healthcare Companies



## ALY HADIBHAI

Managing Director

### ONCAP Management Partners

Aly Hadibhai joined ONCAP in 2012. Previously, he worked at Callisto Capital in Toronto, which is now known as Clearspring Capital.

Aly is a Chartered Financial Analyst. Aly holds undergraduate and graduate degrees from the University of Waterloo and MBA from Stanford University's Graduate School of Business.

Aly focuses on ONCAP's origination, due diligence, portfolio company development efforts in the consumer healthcare sector of emphasis and lead ONCAP's investment in Ideal Dental.



## MICHAEL RESLINSKI

Principal,  
Healthcare & Life Sciences  
Sixth Street

Michael Reslinski is a Principal on the Healthcare and Life Sciences team at Sixth Street. Michael focuses on investments across three themes: biopharma (therapeutics & diagnostics), pharma services (CROs, CDMOs and life science tools) and healthcare data.

Prior to joining Sixth Street, Michael was a Director at DRI Capital, a life sciences royalty monetization firm. Prior to that, Michael advised pharma and biotech clients as a consultant at ZS Associates.

Michael holds a BSc in Genetics from the University of Toronto, MA in Biotechnology from Columbia University and MBA from Harvard Business School.

**BBHC  
2023**

**BLOOM BURTON & CO.  
HEALTHCARE INVESTOR CONFERENCE**

**APRIL 25-26, 2023**

# **COCKTAIL RECEPTION**




**APRIL 25, 2023**

# **ARIA RISTORANTE**

25 YORK ST  
TORONTO, ON  
M5J 2V5

**DOORS OPEN AT 5:00 PM**



---

## PRESENTING COMPANIES

This year's Bloom Burton & Co. Healthcare Investor Conference hosts 66 of Canada's premier publicly-traded and venture-backed private companies as well as promising pre-venture companies in the healthcare industry in the following five areas.





**BIOTECHNOLOGY**  
**HEALTHCARE SERVICES/DIGITAL HEALTH**  
**MEDICAL TECHNOLOGY**  
**SPECIALTY PHARMACEUTICALS**  
**TOOLS**

---

**BIOTECHNOLOGY****NASDAQ: ABCL**

---

**AbCellera Biologics**Tuesday, April 25, 2023 | 9:30 AM  
Room 104 C/D

---

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.

---

**BIOTECHNOLOGY****PRIVATE**

---

**Acuitas Therapeutics**Tuesday, April 25, 2023 | 1:30 PM  
Room 104 C/D

---

Founded in February 2009, Vancouver-based Acuitas Therapeutics is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). They partner with pharmaceutical companies, biotechnology organizations and academic institutes to advance nucleic acid therapeutics to the clinical trial phase and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on the internationally recognized capabilities in delivery technology developed by Acuitas Therapeutics.

Acuitas Therapeutics is known globally as a leader in the field of lipid nanotechnology. The team, led by co-founder Dr. Thomas Madden, is made up of highly experienced scientists, researchers and business professionals – all of whom are focused on excellence in their respective roles and as a company.

---

**MEDICAL TECHNOLOGY****PRIVATE**

---

**Adaptiiv Medical Technologies**Wednesday, April 26, 2023 | 4:00 PM  
Room 104 A

---

Adaptiiv Medical Technologies Inc. has a software platform that works in conjunction with 3D printing to create medical devices for use in radiation oncology. Adaptiiv is shaping the future of personalized healthcare through innovation and collaboration with industry leaders throughout the world.

---

**HEALTHCARE SERVICES/DIGITAL HEALTH****PRIVATE**

---

**AlayaCare**Wednesday, April 26, 2023 | 10:00 AM  
Room 104 C/D

---

AlayaCare offers an end-to-end software platform for governments, home-based care organizations, and community care providers to manage the entire client lifecycle, including needs assessments, care plans, scheduling and visit verification. Combining traditional in-home and virtual care solutions, AlayaCare enables care providers across the world to propel towards innovation and healthcare of the future.

---

**BIOTECHNOLOGY****TSX: ATE****Antibe Therapeutics****Wednesday, April 26, 2023 | 1:30 PM  
Room 104 B**

---

Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The Company's current pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today's NSAIDs for acute pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company's next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

---

**BIOTECHNOLOGY****TSX: APLI****Appili Therapeutics****Wednesday, April 26, 2023 | 3:30 PM  
Room 104 B**

---

Appili Therapeutics is an infectious disease and biodefense biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection.

**TOOLS****PRIVATE****ARTMS**

Tuesday, April 25, 2023 | 10:30 AM  
Room 104 A



Based in Burnaby, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world's most-used diagnostic imaging isotopes. ARTMS' flagship product, the QUANTM Irradiation System (QIS), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 ( $^{68}\text{Ga}$ ), zirconium-89 ( $^{89}\text{Zr}$ ), technetium-99m ( $^{99\text{m}}\text{Tc}$ ) and copper-64 ( $^{64}\text{Cu}$ ) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.

**HEALTHCARE SERVICES/DIGITAL HEALTH****PRIVATE****AtomVie Global Radiopharma**

Tuesday, April 25, 2023 | 11:00 AM  
Room 104 A



AtomVie, officially launched in August 2022 with the successful closing of its series A financing of \$40M by Avego. AtomVie, a spinout of the Centre for Probe Development and Commercialization (CPDC), is a global leading CDMO for the GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. Building upon the expertise developed at the CPDC and its reputation as high-quality radiopharmaceutical CDMO, AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves 10 international clients conducting studies in over 17 countries worldwide.

## HEALTHCARE SERVICES/DIGITAL HEALTH

PRIVATE

**Bayshore HealthCare**

Wednesday, April 26, 2023 | 10:30 AM  
Room 104 C/D



Bayshore HealthCare (Bayshore) is one of the country's leading providers of home and community health care services and is a Canadian-owned company. With locations across the country, including 82 home care offices, 11 pharmacies and 100 community care clinics, Bayshore has more than 15,000 staff members and provides care to over 350,000 clients annually. Its services are purchased by government care programs, insurance companies, workers' compensation boards, health care organizations, the corporate sector and the public. The Bayshore brand extends across three business divisions: Bayshore Home Health (medical and non-medical home care and staffing services), Bayshore Home Care Solutions (home care services for government care programs), Bayshore Specialty Rx (specialty pharmacy, infusion and pharmaceutical patient support services), in addition to two innovation teams: Integrated Care Solutions and Bayshore Digital. The company's goal is to enhance the quality of life, well-being, dignity and independence of Canadians of all ages. Bayshore HealthCare has been a recipient of Canada's Best Managed Companies award since 2006. In 2017, Bayshore HealthCare launched the Bayshore Foundation for Empowered Living to assist those living with illness, injury or aging reclaim or maintain their independence.

## BIOTECHNOLOGY

CSE: BETR

**BetterLife Pharma**

Wednesday, April 26, 2023 | 3:00 PM  
Room 104 B



BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and noncontrolled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

---

**TOOLS****PRIVATE**

---

**ARTMS**Tuesday, April 25, 2023 | 10:30 AM  
Room 104 A

---

Based in Burnaby, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world's most-used diagnostic imaging isotopes. ARTMS' flagship product, the QUANTM Irradiation System (QIS), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.

---

**SPECIALTY PHARMACEUTICALS****TSX-V: RX**

---

**BioSyent**Tuesday, April 25, 2023 | 2:00 PM  
Room 104 B

---

BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

---

**MEDICAL TECHNOLOGY****PRIVATE****Canary Medical**Wednesday, April 26, 2023 | 11:30 AM  
Room 104 C/D

---

Canary Medical is best known for designing, developing and now commercializing (with Zimmer Biomet) the world's first "smart total knee replacement" (Breakthrough Designation), which is the result of combining Canary's sensor, power and telemetry technology with Zimmer's Persona TKA (the best selling knee in the world). Canary's vision is that continuous monitoring of the unique data produced from implants will lead to improved outcomes at lower overall cost. Beyond the knee, Canary has follow-on programs in smart hips (Breakthrough Designation), shoulder (Breakthrough Designation), spine, structural heart, neurovascular applications, aesthetics, plus others.

Canary is led by Bill Hunter, MD, a seasoned entrepreneur with previous experience founding and leading a successful medical device company based on breakthrough technology (Angiotech). Canary's team is globally regarded for its medical device design and development expertise. Headquartered in Vancouver, with U.S. offices in Carlsbad, CA, Canary Medical has 115 employees, half of which are data scientists and half are device engineers.

---

**HEALTHCARE SERVICES/DIGITAL HEALTH****TSX: CRRX****CareRx**Tuesday, April 25, 2023 | 4:00 PM  
Room 104 C/D

---

CareRx is Canada's leading provider of pharmacy services to seniors living communities. We serve over 93,000 residents in over 1,600 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

---

**BIOTECHNOLOGY****NASDAQ: KDNV****Chinook Therapeutics****Tuesday, April 25, 2023 | 10:00 AM  
Room 104 C/D**

---

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

---

**SPECIALTY PHARMACEUTICALS****TSX: CPH****Cipher Pharmaceuticals****Tuesday, April 25, 2023 | 10:30 AM  
Room 104 B**

---

Cipher is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the U.S., and South America.

Cipher operates a lean corporate structure, employs strategic operational partnerships, out and in-licenses products, in addition to making selective investments in drug development to assemble a broad portfolio of prescription products.

---

**MEDICAL TECHNOLOGY****PRIVATE****Clarius**Wednesday, April 26, 2023 | 2:00 PM  
Room 104 A

---

Today, as many as 25 million medical professionals globally do not have access to medical imaging, which is proven to improve patient care and reduce healthcare costs. As pioneers in miniaturizing ultrasound, we're on a mission to make medical imaging accessible everywhere by delivering high-performance, affordable and easy-to-use solutions with the power of artificial intelligence. We're miniaturizing high quality point-of-care ultrasound to offer a safe and cost-effective option for clinicians in every specialty.

---

**HEALTHCARE SERVICES/DIGITAL HEALTH****TSX-V: DOC****CloudMD Software & Services**Wednesday, April 26, 2023 | 3:30 PM  
Room 104 C/D

---

CloudMD is an innovative North American healthcare service provider focused on empowering healthier living by combining leading edge technology with an exceptional national network of healthcare professionals. Every day, our employees and health care providers live our values of delivering excellence, collaboration, connected communication and accountability to solve complex health problems. CloudMD's industry leading workplace health and wellbeing solution, Kii, supports members and their families with a personalized and connected healthcare experience across mental, physical and occupation health. Kii delivers superior clinical health outcomes, consistent high engagement, and measurable ROI for payers such as employers, educational institutions, associations, government, and insurers. CloudMD is also a market leader in workplace absence management through data-driven prevention, intervention and return to work programs. In addition, the Company sells health and productivity tools to hospitals, clinics, and other healthcare service providers to empower them to deliver better care.

---

**BIOTECHNOLOGY****PRIVATE**

---

**Congruence Therapeutics**Wednesday, April 26, 2023 | 11:30 AM  
Room 104 AThe logo for Congruence TX, featuring the word "congruence" in a lowercase, sans-serif font with a blue-to-teal gradient, followed by "TX" in a smaller, dark blue font.

---

Congruence Therapeutics is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Using structural bioinformatics, computational chemistry, and machine learning, the Company is deploying an in silico platform that enables the design of new pharmacological stabilizers, a validated class of small molecules, at an unprecedented speed and scale.

---

**BIOTECHNOLOGY****PRIVATE**

---

**Deep Genomics**Wednesday, April 26, 2023 | 10:30 AM  
Room 104 AThe logo for Deep Genomics, featuring a stylized teal circular icon with a white DNA double helix inside, followed by the words "deep genomics" in a lowercase, sans-serif font with a teal-to-blue gradient.

---

Deep Genomics is a biopharmaceutical company that aims to revolutionize drug development by leveraging expertise in artificial intelligence (AI) to decode RNA biology. Our proprietary platform, the AI Workbench, enables us to decode the enormous complexity of RNA biology to find novel targets, mechanisms, and molecules that are not accessible through traditional methods. We use this advanced technology to develop steric-blocking oligonucleotides (SBOs) that achieve expression increase for the treatment of genetic disease. Founded in 2015, our multidisciplinary team includes expertise in a diverse range of disciplines including those found in a traditional drug company, as well as machine learning, laboratory automation, and software engineering. Deep Genomics is located in Toronto, Ontario and Cambridge, Massachusetts.

---

**SPECIALTY PHARMACEUTICALS****TSX: DHT.UN | DHT.U****DRI Healthcare Trust**Tuesday, April 25, 2023 | 10:00 AM  
Room 104 B

---

DRI Healthcare Trust is managed by DRI Capital Inc. ("DRI Capital"), the pioneer in global pharmaceutical royalty monetization with a more than 30-year history of accelerating innovation by providing capital to inventors, academic institutions and biopharma companies. Since our founding in 1989, DRI Capital has deployed more than US\$2.5 billion, acquiring more than 60 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara.

---

**BIOTECHNOLOGY****PRIVATE****Entos Pharmaceuticals**Tuesday, April 25, 2023 | 2:30 PM  
Room 104 A

---

A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

---

**BIOTECHNOLOGY****NASDAQ: EPIX****ESSA Pharma**Tuesday, April 25, 2023 | 2:00 PM  
Room 104 C/D

---

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.

---

**BIOTECHNOLOGY****TSX: EPRX****Eupraxia Pharmaceuticals**Tuesday, April 25, 2023 | 10:30 AM  
Room 104 C/D

---

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

Eupraxia's lead product candidate, EP-104IAR, is currently in Phase 2 development for the treatment of pain due to osteoarthritis of the knee. The EP-104 platform has expanded into gastrointestinal disease with the launch of a Phase 1b/2a program to treat eosinophilic esophagitis. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for both other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

## MEDICAL TECHNOLOGY

PRIVATE

**Exact Imaging**

Wednesday, April 26, 2023 | 2:30 PM  
Room 104 A



Exact Imaging is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging's ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system's 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application have received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).

## SPECIALTY PHARMACEUTICALS

PRIVATE

**FORUS Therapeutics**

Tuesday, April 25, 2023 | 3:30 PM  
Room 104 B



FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. Our mission is to bring solutions to cancer patients, caregivers, physicians and our partners by accelerating unique and important treatments that meaningfully enhance life.

## BIOTECHNOLOGY

NASDAQ: FUSN

**Fusion Pharmaceuticals**Tuesday, April 25, 2023 | 3:00 PM  
Room 104 C/D

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's first program, FPI-1434 targeting insulin-like growth factor 1 receptor (IGF-1R), is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), currently in a Phase 1 study; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), which has received FDA investigational new drug (IND) clearance and will begin a Phase 1 study. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRIs) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the company has signed strategic agreements for actinium supply with TRIUMF, Niowave, Inc. and BWXT Medical Ltd.

## BIOTECHNOLOGY

PRIVATE

**Gandeeva Therapeutics**Tuesday, April 25, 2023 | 1:30 PM  
Room 104 A

Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva's structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada.

---

**SPECIALTY PHARMACEUTICALS****TSX-V: WOLF****Grey Wolf Animal Health**Tuesday, April 25, 2023 | 2:30 PM  
Room 104 B

---

Grey Wolf Animal Health Corp., headquartered in Toronto, Canada, is a diversified animal health company founded by a veterinarian to bring to market a broad portfolio of products that meets the unmet needs of veterinarians, clinics and pets. The Company's strategy is to in-license, acquire or develop innovative prescription and non-prescription products for commercialization in the veterinarian channel in Canada.

---

**MEDICAL TECHNOLOGY****TSX-V: HTL****Hamilton Thorne**Wednesday, April 26, 2023 | 9:30 AM  
Room 104 B

---

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, Tek-Event brands, and Microptic, through its growing sales force and distributors worldwide. Hamilton Thorne's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

## BIOTECHNOLOGY

NASDAQ: FUSN

**Fusion Pharmaceuticals**

Tuesday, April 25, 2023 | 3:00 PM  
Room 104 C/D



Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's first program, FPI-1434 targeting insulin-like growth factor 1 receptor (IGF-1R), is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), currently in a Phase 1 study; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), which has received FDA investigational new drug (IND) clearance and will begin a Phase 1 study. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRIs) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the company has signed strategic agreements for actinium supply with TRIUMF, Niowave, Inc. and BWXT Medical Ltd.

## BIOTECHNOLOGY

PRIVATE

**Gandeeva Therapeutics**

Tuesday, April 25, 2023 | 1:30 PM  
Room 104 A



Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva's structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada.

---

**SPECIALTY PHARMACEUTICALS****TSX-V: WOLF****Grey Wolf Animal Health**Tuesday, April 25, 2023 | 2:30 PM  
Room 104 B

---

Grey Wolf Animal Health Corp., headquartered in Toronto, Canada, is a diversified animal health company founded by a veterinarian to bring to market a broad portfolio of products that meets the unmet needs of veterinarians, clinics and pets. The Company's strategy is to in-license, acquire or develop innovative prescription and non-prescription products for commercialization in the veterinarian channel in Canada.

---

**MEDICAL TECHNOLOGY****TSX-V: HTL****Hamilton Thorne**Wednesday, April 26, 2023 | 9:30 AM  
Room 104 B

---

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, Tek-Event brands, and Microptic, through its growing sales force and distributors worldwide. Hamilton Thorne's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

---

**SPECIALTY PHARMACEUTICALS****TSX: HLS**

---

**HLS Therapeutics**Tuesday, April 25, 2023 | 11:30 AM  
Room 104 B

HLS Therapeutics®

---

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

---

**MEDICAL TECHNOLOGY****PRIVATE**

---

**Intellijoint Surgical**Wednesday, April 26, 2023 | 3:00 PM  
Room 104 A

---

Intellijoint Surgical® develops and commercializes surgical planning & navigation solutions for total hip and knee joint replacements, as well as digital patient engagement for all orthopaedic specialties. It is committed to improving patients' lives by providing every surgeon with effective, easy-to-use technology to manage the entire episode of care. Intellijoint's technology is used by top orthopaedic institutions and surgeons globally.

---

**SPECIALTY PHARMACEUTICALS****TSX: IGX****IntelGenx**Wednesday, April 26, 2023 | 4:00 PM  
Room 104 B

---

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm<sup>®</sup>, DisinteQ<sup>™</sup>, VetaFilm<sup>™</sup> and transdermal VevaDerm<sup>™</sup>, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

---

**BIOTECHNOLOGY****PRIVATE****Inversago Pharma**Wednesday, April 26, 2023 | 11:00 AM  
Room 104 A

---

Inversago Pharma is a privately owned, clinical stage, Canadian biotech company, specialized in the development of new therapies focusing on C1 blockades, based on first-in-class, peripherally-acting C1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions.

---

**BIOTECHNOLOGY****PRIVATE****KisoJi Biotechnology**Tuesday, April 25, 2023 | 3:30 PM  
Room 104 A

---

KisoJi is an antibody company that is revolutionizing the discovery and development of antibody therapeutics. Its antibody platform includes the first multi-species VH/VHH single domain antibody transgenic mouse, an AI-enabled antibody paratope fingerprinting and search technology, and a modular, easily manufacturable multi-specific antibody format. From this platform, the Company has developed a preclinical pipeline that includes tri-specific immuno-oncology antibodies for both solid and hematologic cancers, as well as the first reported single domain TROP2 antibody that can cause robust tumor regression in preclinical models without the need for a drug conjugate.

---

**SPECIALTY PHARMACEUTICALS****TSX: GUD****Knight Therapeutics**Tuesday, April 25, 2023 | 1:30 PM  
Room 104 B

---

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM.

---

**SPECIALTY PHARMACEUTICALS****PRIVATE****Kye Pharmaceuticals**Tuesday, April 25, 2023 | 4:00 PM  
Room 104 B

---

KYE Pharmaceuticals Inc. (KYE) is a private company headquartered in Mississauga, Canada focused on bringing medications to the Canadian market which fulfill clinically significant and unmet needs. KYE has licensed many innovative products and was founded on an entrepreneurial spirit that optimizes our team's strengths and brings unique value to our partners, Canadian healthcare professionals, and most importantly, our patients.

---

**HEALTHCARE SERVICES/DIGITAL HEALTH****TSX: LSPK****LifeSpeak**Wednesday, April 26, 2023 | 2:00 PM  
Room 104 C/D

---

LifeSpeak is a leading software-as-a-service provider of a platform for mental health and total wellbeing education for organizations committed to taking care of their employees and customers. With 18+ years of experience creating and curating thousands of expert-led micro-learning videos and other digital content, LifeSpeak's proprietary library's depth and breadth of easily consumable content helps companies around the world support their people anytime and anywhere. LifeSpeak serves a diverse global client base across many industries and sectors, including Fortune 500 companies, government agencies, insurance providers, and other health technology firms. LifeSpeak is the parent company of Lift Digital Inc. ("LIFT session"), ALAViDA Health Ltd. ("ALAViDA"), EnCompass Education Solutions ("Torchlight") and Wellbeats Inc. ("Wellbeats").

**SPECIALTY PHARMACEUTICALS****TSX: MDP****Medexus Pharmaceuticals**

Tuesday, April 25, 2023 | 9:30 AM  
 Room 104 B



Medexus is a leader in innovative and rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. Our current focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy. We continue to build a highly differentiated company with a growing portfolio of innovative and high-value orphan and rare disease products that will underpin our growth for the next decade.

Our current leading products are IXINITY<sup>®</sup>, Rasuvo<sup>®</sup> and Metoject<sup>®</sup>, Rupall<sup>®</sup>, and Gleolan<sup>®</sup> (aminolevulinic acid hydrochloride or ALA HCl). We have also licensed treosulfan, part of a preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, for commercialization in the United States and Canada. Our mission is to provide the best healthcare products to healthcare professionals and patients. We strive to deliver on this mission by acting on our core values: Quality, Innovation, Customer Service, and Collaboration.

**BIOTECHNOLOGY****TSX: MDNA | NASDAQ: MDNA****Medicenna Therapeutics**

Tuesday, April 25, 2023 | 3:30 PM  
 Room 104 C/D



Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna's early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically "cold" tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

**MEDICAL TECHNOLOGY****TSX: MBX****Microbix Biosystems**

Wednesday, April 26, 2023 | 11:30 AM  
 Room 104 B



Microbix creates proprietary biological products for human health, with over 100 skilled employees and annualized sales targeting C\$ 2.0 million per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by IWA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA., Labquality Oy, The Medical Supply Company of Ireland, Neo-Science Equipment LLC, R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc., and Thomas Scientific LLC. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is headquartered in Mississauga, Ontario, Canada.

**HEALTHCARE SERVICES/DIGITAL HEALTH****TSX-V: NPTH****NeuPath Health**

Wednesday, April 26, 2023 | 4:00 PM  
 Room 104 C/D



NeuPath Health Inc. operates an integrated network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care, enabling each individual we treat to live their best life.

The Company operates an interdisciplinary network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions.

In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers.

---

**HEALTHCARE SERVICES/DIGITAL HEALTH****TSX-V: NEWU****Newtopia**

Wednesday, April 26, 2023 | 3:00 PM  
Room 104 C/D



---

Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans.

---

**TOOLS****PRIVATE****Nicoya Lifesciences**

Tuesday, April 25, 2023 | 9:30 AM  
Room 104 A



---

Nicoya is a lifesciences tools company providing a breakthrough digital proteomics platform for researchers in biopharma to help them accelerate the discovery of new therapeutics. Nicoya has products in over 50 countries and has been cited in over 300 peer reviewed journal articles, with customers ranging from world class academic institutions to top 10 pharma. Nicoya's platform addresses a multi-billion dollar market opportunity and is becoming a standard tool for the discovery and development of new therapeutics that help address some of the world's most impactful diseases.

---

**MEDICAL TECHNOLOGY****TSX: OPS****OpSens**

Wednesday, April 26, 2023 | 10:30 AM  
 Room 104 B



OpSens focuses mainly in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of 200,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens has recently received FDA clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). This unique guidewire is a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access. OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

---

**MEDICAL TECHNOLOGY****PRIVATE****Panthera Dental**

Wednesday, April 26, 2023 | 3:30 PM  
 Room 104 A



Panthera Dental is committed to design and manufacture custom-made dental restorations, sleep breathing disorder solutions and implantology products using proprietary CAD/CAM processes, smart manufacturing and superior quality materials. Panthera's highly skilled and passionate team is dedicated to provide the highest quality outcomes and to deliver state-of-the-art solutions to dental, medical and sleep professionals who strive to improve patients' quality of life worldwide.

---

**MEDICAL TECHNOLOGY****TSX-V: PINK****Perimeter Medical Imaging**Wednesday, April 26, 2023 | 11:00 AM  
Room 104 B

---

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US\$7.4 million awarded by the Cancer Prevention and Research Institute of Texas.

The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

---

**BIOTECHNOLOGY****NASDAQ: PNT****POINT Biopharma**Wednesday, April 26, 2023 | 2:00 PM  
Room 104 B

---

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (225Ac) and lutetium-177 (177Lu). POINT's active clinical trials include FRONTIER, the phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-a (FAP-a), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment.

---

**MEDICAL TECHNOLOGY****TSX: PRN | NASDAQ: PROF****Profound Medical**Wednesday, April 26, 2023 | 10:00 AM  
Room 104 B**PROFOUND**

---

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO<sup>®</sup>, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO<sup>®</sup> is CE marked and received 510(k) clearance from the U.S. Food and Drug Administration in August 2019.

Profound is also commercializing Sonalleve<sup>®</sup>, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve<sup>®</sup> has also been approved by the China Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve<sup>®</sup> where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

---

**BIOTECHNOLOGY****PRIVATE****Radiant Biotherapeutics**Tuesday, April 25, 2023 | 4:00 PM  
Room 104 A

---

Radiant Biotherapeutics is leading the new frontier of multi-valent, multi-specific antibody therapeutics. The proprietary Multabody platform engineers stronger-binding, highly-efficacious antibodies that can hit multiple targets with much higher potency than other antibody platforms. These powerful Multabodies have potential to be a new class of biologics to tackle complex, heterogenous diseases, such as cancer, that often have challenging targets and mechanisms. Multabody synthesis and manufacturing is flexible, modular and scalable, and leverages existing, traditional processes. The groundbreaking efficiency of the platform is driving a novel pipeline of mono-, bi- and tri-specific Multabody treatments in oncology. Strategic partnerships with the Bill and Melinda Gates Foundation and two leading biopharmaceutical companies validate the platform and its broad scientific and clinical utility.

BIOTECHNOLOGY

TSX:REUN | NASDAQ:REUN

**Reunion Neuroscience**

Wednesday, April 26, 2023 | 2:30 PM  
Room 104 B



Reunion is committed to developing innovative therapeutic solutions for underserved mental health conditions. The Company's lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions. The U.S. Patent and Trademark Office has granted the Company a patent for the claims related to RE104, granting it exclusive rights to the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including RE104. The patent will provide protection until 2041. Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.

BIOTECHNOLOGY

TSX-V: MSCL

**Satellos Bioscience**

Tuesday, April 25, 2023 | 11:30 AM  
Room 104 C/D



Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.

---

**SPECIALTY PHARMACEUTICALS****PRIVATE**

---

**Searchlight Pharma**Tuesday, April 25, 2023 | 3:00 PM  
Room 104 B**SEARCHLIGHT**  
PHARMA

---

Searchlight Pharma Inc., headquartered in Montreal, is a leading Canadian-based specialty healthcare company that executes best-in class search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products. Our core products focus on women's health, urogynecology, and urology, and our team is committed to improving people's lives by bringing the right products to market.

---

**MEDICAL TECHNOLOGY****PRIVATE**

---

**Synaptive Medical**Wednesday, April 26, 2023 | 1:30 PM  
Room 104 A**Synaptive**

---

Synaptive Medical Inc., a Toronto-based, global medical device and technology company, solves surgical, imaging, and data challenges to improve the quality of human lives. Synaptive's integrated suite of products – bridging MRI, surgical planning, navigation, and robotic visualization – delivers novel information with automated efficiency across all stages of clinical intervention.

**BIOTECHNOLOGY****TSX: TH | NASDAQ: THTX****Theratechnologies**

Tuesday, April 25, 2023 | 11:30 AM  
Room 104 A



Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor. Theratechnologies is pursuing the development of tesamorelin for the treatment of nonalcoholic steatohepatitis - or NASH - in the general population. The Company continues to have discussions with potential partners with resources and capabilities for the conduct of a Phase 2b/3 study.

**HEALTHCARE SERVICES/DIGITAL HEALTH****TSX-V: THNK****Think Research**

Wednesday, April 26, 2023 | 11:00 AM  
Room 104 C/D



Think Research is a rapidly-growing healthcare software company based in downtown Toronto. Our mission is to organize the world's health knowledge so that everyone gets the best care.

Our point-of-care, clinical decision support tools are used by health systems and healthcare providers (i.e. doctors, nurses, pharmacists, and more) to dramatically improve healthcare outcomes, save clinicians' time, and reduce administrative burdens and costs.

Today, with a growing network of clients, collaborators and partners, this principle of collaboration is supported by our entire suite of applications. Deployed in over 2,200 health care facilities across Canada, the US and around the world, our tools are transforming healthcare, one clinical support tool at a time.

BIOTECHNOLOGY

PRIVATE

**Thryv Therapeutics**Tuesday, April 25, 2023 | 2:00 PM  
Room 104 A

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.), is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019, and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers and complement existing therapies.

BIOTECHNOLOGY

PRIVATE

**Triumvira Immunologics**Wednesday, April 26, 2023 | 9:30 AM  
Room 104 A

Triumvira Immunologics, Inc. is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario, and South San Francisco, California.

---

**SPECIALTY PHARMACEUTICALS****CSE:VPH****Valeo Pharma**

Tuesday, April 25, 2023 | 11:00 AM  
Room 104 B



---

Valeo Pharma is a fast growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has all the necessary capabilities and a complete infrastructure to register and manage its growing product portfolio through all stages of commercialization.

---

**BIOTECHNOLOGY****PRIVATE****Ventus Therapeutics**

Wednesday, April 26, 2023 | 10:00 AM  
Room 104 A



---

Ventus Therapeutics is a biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets, with an initial focus on immunology, inflammation and neurology. The Company's proprietary drug discovery platform ReSOLVE gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic blueprints that can guide the development of differentiated therapies at a fast pace. Ventus' first target screen was conducted in 2020, which led to the nomination of three development candidates in 2022, including: VENT-03, a potential first-in-class cGAS inhibitor; VENT-02, a brain-penetrant NLRP3 inhibitor; and VENT-01, a peripherally restricted NLRP3 inhibitor that is partnered with Novo Nordisk. These programs exemplify Ventus' unique discovery capabilities and focus on first- and best-in-class programs for multi-indication immunology targets with franchise potential.

---

**HEALTHCARE SERVICES/DIGITAL HEALTH**    **TSX: VMD | NASDAQ: VMD**

---

**VieMed Healthcare**Wednesday, April 26, 2023 | 2:30 PM  
Room 104 C/D

VieMed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. VieMed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology.

---

**TOOLS****PRIVATE**

---

**Virica Biotech**Tuesday, April 25, 2023 | 10:00 AM  
Room 104 A

Virica is a viral vector enhancer company, developing unique products called VSEs to optimize the manufacturing of medicines such as gene therapies, vaccines and cell therapies. VSEs enhance production by reducing antiviral defences in cells, allowing developers to economically and efficiently produce therapies at scale. Customized VSE formulations substantially increase manufacturing yields and reduce the cost of goods. Virica's business is selling and developing VSE formulas to developers, CDMOs and reagent producers in order to facilitate the efficient production of vital medicines.

---

**HEALTHCARE SERVICES/DIGITAL HEALTH****TSX: VHI****VitalHub**

Wednesday, April 26, 2023 | 1:30 PM  
Room 104 C/D



---

Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.

VitalHub provides technology to Health and Human Services providers including Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination & Optimization, and Patient Flow & Operational Visibility solutions.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently VitalHub serves more than 400 clients across Canada, USA, UK, Australia, the Middle East, and Europe.

VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 300 team members globally.

---

**HEALTHCARE SERVICES/DIGITAL HEALTH****TSX: WELL****WELL Health Technologies**

Wednesday, April 26, 2023 | 9:30 AM  
Room 104 C/D



---

WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end-to-end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth offering.

---

**BIOTECHNOLOGY****NASDAQ: XENE**

---

**Xenon Pharmaceuticals**Tuesday, April 25, 2023 | 11:00 AM  
Room 104 C/D

---

Xenon Pharmaceuticals is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.

---

**BIOTECHNOLOGY****PRIVATE**

---

**Zucara Therapeutics**Tuesday, April 25, 2023 | 3:00 PM  
Room 104 A

---

Zucara Therapeutics is developing ZT-01, a first-in-class therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels) in patients using insulin therapy. Zucara has demonstrated that ZT-01 restores glucagon release required to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life. Zucara is planning a US\$15M Series B financing in 2023 that will advance ZT-01 into a Phase 2 study in Type 1 diabetes, expand into Type 2 diabetes and develop a long-acting injectable formulation.

---

**BIOTECHNOLOGY****NYSE: ZYME****Zymeworks**Tuesday, April 25, 2023 | 2:30 PM  
Room 104 C/D

---

Zymeworks Inc. is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly-owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.

---

---

# BLOOM BURTON & CO.



## FOR THE LAST 15 YEARS

THE BLOOM BURTON TEAM HAS BEEN EXCLUSIVELY DEDICATED TO THE CANADIAN HEALTHCARE INVESTMENT INDUSTRY.

WE CONTINUE TO SERVE INVESTORS AND COMPANIES SEEKING TO MAKE AN IMPACT IN HEALTHCARE AND BIOTECH.

WE ARE COMMITTED TO SUPPORTING AND CELEBRATING THE SUCCESSES AND STORIES DRIVING OUR ECOSYSTEM FORWARD.

The Bloom Burton & Co. team has deep knowledge in medicine, science, patent and corporate law, finance, and healthcare invention, development and commercialization. We are the ideal group to help companies plan their capital market strategies, investigate the relevance of new biological pathways, consider new therapeutic indications and clinical designs, and catalogue and diligence new products or companies for acquisition.

By speaking with large companies and investors every day, we know what they are looking for.

We identify the most impactful companies for our investor network and we provide tailor-made support solutions for management teams and boards of healthcare companies.

---

## SERVICES



**OUR SERVICES HELP IDENTIFY,  
CULTIVATE AND CREATE INVESTMENT  
OPPORTUNITIES IN THE HEALTHCARE  
SECTOR ON BEHALF OF COMPANIES  
AND INVESTORS.**

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, digital health, life science tools, animal health, nutrition and wellness.

---

**OUR SEVEN BUSINESS SERVICES WORK  
COHESIVELY TO ACCELERATE  
MONETIZATION FOR BOTH COMPANY  
AND INVESTOR CLIENTS.**

---

**1**

---

**RAISING CAPITAL &  
FINANCING**

Sourcing equity and debt capital for private and public companies

---

---

**2**

---

**M&A ADVISORY**

Enabling monetization through strategic transactions

---

---

**3**

---

**EQUITY RESEARCH**

Influential opinions and insights on companies

---

---

**4**

---

**SALES & TRADING**

Generating returns for investors

---

---

**5**

---

**MONETIZATION PLANNING**

Scientific and business advisory services

---

---

**6**

---

**DIRECT INVESTMENT**

Discretionary and principal investments

---

---

**7**

---

**COMPANY CREATION**

Establishing and incubating new healthcare companies

---

---

## SPONSORS



mccarthy  
tetraault

M  
MINTZ

newsfile

NORTON ROSE  
FULBRIGHT

TMX THE FUTURE  
IS YOURS TO SEE.

TORYS  
LLP

troutman  
pepper

Zeifmans  
Ideas with impact

**THANK YOU!**

TO OUR 2023 SPONSORS FOR  
THEIR GENEROUS SUPPORT!

# CONFERENCE INFORMATION

## COMPANY PRESENTATIONS

Room 104 A  
Room 104 B  
Room 104 C/D

## 1X1 MEETINGS

Room 105

## KEYNOTE ADDRESS AND PANEL DISCUSSIONS

Plenary Room  
Room 106/107


## QUESTION OR LOST AND FOUND

Registration Booth

## WI-FI

**Network Name**  
Bloom Burton & Co.

**Access Code**  
BBHIC2023





2023 Bloom Burton  
Award Gala

*September 28, 2023*

Four Seasons Hotel  
Toronto, Ontario  
60 Yorkville Avenue

Sponsorship Contact: [bbloom@bloomburton.com](mailto:bbloom@bloomburton.com)



bloom burton & co

/accelerating returns in healthcare<sup>®</sup>

 @bloomburton

 Bloom Burton & Co.

#BBHIC2023